TABLE 2.
Assay and result | % Sensitivityb (95% CI) | No. of cases with RT-PCR result |
|
---|---|---|---|
Positive | Negative | ||
MN1:40c | 82.8 (70.1, 91.0) | ||
+ | 48 | 9 | |
− | 10 | 55 | |
‡MN1:20d | 84.5 (72.1, 92.2) | ||
+ | 49 | 13 | |
− | 9 | 51 | |
HAI1:40c | 60.3 (46.6, 72.7) | ||
+ | 35 | 4 | |
− | 23 | 60 | |
HAI1:20d | 70.7 (57.1, 81.5) | ||
+ | 41 | 7 | |
− | 17 | 57 |
HAI, hemagglutinin inhibition assay. MN, microneutralization assay. CI, confidence interval. +, evidence of seroconversion. −, absence of seroconversion. MN1:40 versus RT-PCR, kappa = 0.69; MN1:20 versus RT-PCR, kappa = 0.64; HAI1:40 versus RT-PCR, kappa = 0.54; HAI1:20 versus RT-PCR, kappa = 0.60.
Serological method sensitivity for detection of RT-PCR confirmed cases.
Seroconversion was defined as an acute-phase serum titer of <1:10 with a convalescent titer of ≥1:40 or a significant increase (≥4-fold) in antibody titers between the two sera.
Seroconversion was defined as an acute-phase serum titer of <1:10 with a convalescent titer of ≥1:20 or a significant increase (≥4-fold) in antibody titers between the two sera.